| [1] |
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin, 2013, 63(1): 11-30.
|
| [2] |
Sedláková I, Tošner J, Kopecký O, et al. Vascular endothelial growth factor in ovarian cancer patients[J]. Ceska Gynekol, 2012, 77 (5): 415-20.
|
| [3] |
Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy[J]. Science, 2005,307(5706): 58 -62.
|
| [4] |
del Carmen MG, Micha J, Small L, et al. A phaseⅡclinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer[J]. Gynecol Oncol, 20 12, 126(3): 369-74.
|
| [5] |
Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase Ⅲ trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer[J]. J Clin Oncol, 2012, 30(17): 2039-45.
|
| [6] |
Cannistra SA, Matulonis UA, Penson RT, et al. Phase Ⅱ study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer[J]. J Clin Oncol, 2007, 25(33): 5180-6.
|
| [7] |
Monk BJ, Han E, Josephs-Cowan CA, et al. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer[J]. Gynecol Oncol, 2006, 102(2): 140-4.
|
| [8] |
O’Malley DM, Richardson DL, Rheaume PS, et al. Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer[J]. Gynecol Oncol, 2011, 121(2): 269-72.
|
| [9] |
Tillmanns TD, Lowe MP, Walker MS, et al. Phase Ⅱ clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma[J]. Gynecol Oncol, 2013, 128(2): 221-8.
|
| [10] |
Wenham RM, Lapolla J, Lin HY, et al. A phase Ⅱ trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy[J]. Gynecol Oncol, 20 13, 130(1): 19-24.
|
| [11] |
Miles DW, Chan A, Dirix LY, et al. Phase Ⅲ study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oncol, 2010, 28(20): 3239-47.
|
| [12] |
Ortholan C, Durivault J, Hannoun-Levi JM, et al. Bevacizumab/ docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment[J]. Eur J Cancer, 2010, 46(16): 3022-36.
|
| [13] |
Verschraegen CF, Czok S, Muller CY, et al. Phase Ⅱ study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer[J]. Ann Oncol, 20 12, 23(12): 3104-10.
|
| [14] |
Kudoh K, Takano M, Kouta H, et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers[J]. Gynecol Oncol, 2011, 122(2): 23 3-7.
|
| [15] |
Barber EL, Zsiros E, Lurain JR, et al. The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer[J]. J Gynecol Oncol, 2013, 24(3): 258-64.
|
| [16] |
Vives M, Ginestà MM, Gracova K, et al. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells[J]. Int J Cancer, 2013, 13 3(10): 2464-72.
|
| [17] |
Matulonis UA, Pereira L, Liu J, et al. Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer[J]. Gynecol Oncol, 2012, 126(1): 41-6.
|
| [18] |
McGonigle KF, Muntz HG, Vuky J, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinumresistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study[J]. Cancer, 2011, 117(16): 3731-40.
|
| [19] |
Hagemann AR, Novetsky AP, Zighelboim I, et al. Phase Ⅱ study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer[J]. Gynecol Oncol, 2013, 131(3): 535-40.
|
| [20] |
Richardson DL, Backes FJ, Seamon LG, et al. Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer[J]. Gynecol Oncol, 2008, 111(3): 461-6.
|
| [21] |
Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model[J]. Clin Cancer Res, 2003, 9(15): 5721-8.
|
| [22] |
Numnum TM, Rocconi RP, Whitworth J, et al. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma[J]. Gynecol Oncol, 2006, 102(3): 42 5-8.
|
| [23] |
Hamilton CA, Maxwell GL, Chernofsky MR, et al. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer[J]. Gynecol Oncol, 2008, 111(3): 530-2.
|
| [24] |
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer[J]. N Engl J Med, 2011, 365(26): 2473-83.
|
| [25] |
Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer[J]. Gynecol Oncol, 2010, 117(3): 49 7-504.
|
| [26] |
Lemmens L, Claes V, Uzzell M. Managing patients with metastatic colorectal cancer on bevacizumab[J]. Br J Nurs, 20 08,17(15): 944-9.
|
| [27] |
Richardson DL, Backes FJ, Hurt JD, et al. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?[J]. Gynecol Oncol, 2010, 11 8(1): 47-51.
|
| [28] |
Simpkins F, Belinson JL, Rose PG. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening[J]. Gynecol Oncol, 2007, 107(1): 118-23.
|
| [29] |
Miller KD. E2100: a phase Ⅲ trial of paclitaxel versus paclitaxel/ bevacizumab for metastatic breast cancer[J]. Clin Breast Cancer, 20 03, 3(6): 421-2.
|
| [30] |
Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab[J]. J Surg Oncol, 2005, 91(3): 17 3-80.
|
下载:
